文献速递慢性肾脏病肾血管病与高血压

MicroRNA-21调控PPARα:4型心肾综合征心脏病理的新分子机制

MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
PubMed 文献 · Kidney Int · 2017-07-29

在5/6肾切除CKD大鼠模型中纵向刻画左心室病理,通过mRNA和miRNA测序发现miR-21-5p升高;抑制miR-21-5p可防止左心室肥厚并改善左心室功能,机制涉及PPARα通路;低剂量PPARα激动剂氯贝特改善心脏功能并防止左心室扩张。

要点

  • 抑制miR-21-5p可保护5/6肾切除大鼠免于左心室肥厚并改善左心室功能。
  • miR-21-5p抑制改变左心室中PPARα调控通路的基因表达。
  • 低剂量PPARα激动剂氯贝特改善5/6肾切除大鼠心脏功能并防止左心室扩张。

核心结论

  • miR-21-5p通过调控PPARα参与CKD相关心脏病理,PPARα是CKD相关心脏功能障碍的潜在治疗靶点。

研究设计与样本

  • 在5/6肾切除CKD大鼠模型中纵向刻画左心室病理,并在疾病进展的生理学不同时点进行左心室mRNA和miRNA二代测序。

主要发现

  • 左心室mRNA和miRNA测序识别出多个免疫、脂质代谢和炎症通路基因改变以及若干miRNA变化。
  • miR-21-5p在数据集中升高,抑制miR-21-5p可保护5/6肾切除大鼠免于左心室肥厚并改善左心室功能。
  • miR-21-5p抑制后左心室PPARα调控通路的基因表达发生改变。
  • 低剂量PPARα激动剂氯贝特治疗改善5/6肾切除大鼠心脏功能并防止左心室扩张。

临床怎么用

  • 在CKD相关心脏功能障碍中可关注miR-21-5p-PPARα轴作为潜在干预靶点。
  • PPARα激动剂(如氯贝特)在CKD心脏病理中的治疗潜力需进一步临床验证。

局限性

  • 研究基于5/6肾切除大鼠模型,结论向人类CKD患者的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular events are the leading cause of death in patients with chronic kidney disease (CKD), although the pathological mechanisms are poorly understood. Here we longitudinally characterized left ventricle pathology in a 5/6 nephrectomy rat model of CKD and identify novel molecular mediators. Next-generation sequencing of left ventricle mRNA and microRNA (miRNA) was performed at physiologically distinct points in disease progression, identifying alterations in genes in numerous immune, lipid metabolism, and inflammatory pathways, as well as several miRNAs. MiRNA miR-21-5p was increased in our dataset and has been reported to regulate many identified pathways. Suppression of miR-21-5p protected rats with 5/6 nephrectomy from developing left ventricle hypertrophy and improved left ventricle function. Next-generation mRNA sequencing revealed that miR-21-5p suppression altered gene expression in peroxisome proliferator-activated receptor alpha (PPARα) regulated pathways in the left ventricle. PPARα, a miR-21-5p target, is the primary PPAR isoform in the heart, importantly involved in regulating fatty acid metabolism. Therapeutic delivery of low-dose PPARα agonist (clofibrate) to rats with 5/6 nephrectomy improved cardiac function and prevented left ventricle dilation. Thus, comprehensive characterization of left ventricle molecular changes highlights the involvement of numerous signaling pathways not previously explored in CKD models and identified PPARα as a potential therapeutic target for CKD-related cardiac dysfunction.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Chuppa S, Liang M, Liu P, et al. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4. Kidney Int. 2017. PMID: 28760335. doi:10.1016/j.kint.2017.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。